PMID- 32903854
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 11
DP  - 2020
TI  - TACE-Sorafenib With Thermal Ablation Has Survival Benefits in Patients With Huge 
      Unresectable Hepatocellular Carcinoma.
PG  - 1130
LID - 10.3389/fphar.2020.01130 [doi]
LID - 1130
AB  - PURPOSE: To investigate the effectiveness and safety of transarterial 
      chemoembolization (TACE) combined with sorafenib and thermal ablation in patients 
      with huge hepatocellular carcinoma (HCC). MATERIALS AND METHODS: This 
      retrospective study examined 50 patients with huge unresectable HCC treated from 
      January 2009 to December 2015. Among them, 28 cases received TACE-sorafenib 
      treatment (TACE-sorafenib group), and 22 cases received TACE-sorafenib plus 
      thermal ablation treatment (TACE-sorafenib-thermal ablation group). The Overall 
      survival (OS), progression-free survival (PFS), and adverse events (AEs) were 
      compared. RESULTS: The median follow-up was 13.5 months (ranges 4.2 to 96.7 
      months). The median OS was significantly longer in the TACE-sorafenib-thermal 
      ablation group than that in the TACE-sorafenib group (20.8 vs. 10.4 months, 
      P=0.003). The median PFS of the ablation and no ablation groups were 4.3 vs. 7.1 
      months (P=0.546). The treatment modality was an independent predictor of OS 
      (P=0.004). There were no notable drug-related high grade adverse events or 
      permanent adverse sequelae. CONCLUSION: TACE-sorafenib-thermal ablation provided 
      extended OS to patients with huge unresectable HCC and could be a better choice 
      than TACE-sorafenib.
CI  - Copyright (c) 2020 Wu, Qi, Cao, Shen, Chen, Xie, Huang, Song, Zhou and Fan.
FAU - Wu, Ying
AU  - Wu Y
AD  - Department of Minimally Invasive Interventional Therapy, Sun Yat-sen University 
      Cancer Center, Guangzhou, China.
AD  - Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, 
      China.
FAU - Qi, Han
AU  - Qi H
AD  - Department of Minimally Invasive Interventional Therapy, Sun Yat-sen University 
      Cancer Center, Guangzhou, China.
AD  - Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, 
      China.
FAU - Cao, Fei
AU  - Cao F
AD  - Department of Minimally Invasive Interventional Therapy, Sun Yat-sen University 
      Cancer Center, Guangzhou, China.
AD  - Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, 
      China.
FAU - Shen, Lujun
AU  - Shen L
AD  - Department of Minimally Invasive Interventional Therapy, Sun Yat-sen University 
      Cancer Center, Guangzhou, China.
AD  - Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, 
      China.
FAU - Chen, Shuanggang
AU  - Chen S
AD  - Department of Minimally Invasive Interventional Therapy, Sun Yat-sen University 
      Cancer Center, Guangzhou, China.
AD  - Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, 
      China.
FAU - Xie, Lin
AU  - Xie L
AD  - Department of Minimally Invasive Interventional Therapy, Sun Yat-sen University 
      Cancer Center, Guangzhou, China.
AD  - Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, 
      China.
FAU - Huang, Tao
AU  - Huang T
AD  - Department of Minimally Invasive Interventional Therapy, Sun Yat-sen University 
      Cancer Center, Guangzhou, China.
AD  - Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, 
      China.
FAU - Song, Ze
AU  - Song Z
AD  - State Key Laboratory of Oncology in South China, Collaborative Innovation Center 
      of Cancer Medicine, Sun Yat-sen University, Guangzhou, China.
FAU - Zhou, Danyang
AU  - Zhou D
AD  - Department of Minimally Invasive Interventional Therapy, Sun Yat-sen University 
      Cancer Center, Guangzhou, China.
AD  - State Key Laboratory of Oncology in South China, Collaborative Innovation Center 
      of Cancer Medicine, Sun Yat-sen University, Guangzhou, China.
FAU - Fan, Weijun
AU  - Fan W
AD  - Department of Minimally Invasive Interventional Therapy, Sun Yat-sen University 
      Cancer Center, Guangzhou, China.
AD  - Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, 
      China.
LA  - eng
PT  - Journal Article
DEP - 20200729
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC7438914
OTO - NOTNLM
OT  - drug resistance
OT  - hepatocellular carcinoma
OT  - sorafenib
OT  - thermal ablation
OT  - transarterial chemoembolization
OT  - treatment
EDAT- 2020/09/10 06:00
MHDA- 2020/09/10 06:01
PMCR- 2020/07/29
CRDT- 2020/09/09 17:58
PHST- 2020/06/15 00:00 [received]
PHST- 2020/07/10 00:00 [accepted]
PHST- 2020/09/09 17:58 [entrez]
PHST- 2020/09/10 06:00 [pubmed]
PHST- 2020/09/10 06:01 [medline]
PHST- 2020/07/29 00:00 [pmc-release]
AID - 10.3389/fphar.2020.01130 [doi]
PST - epublish
SO  - Front Pharmacol. 2020 Jul 29;11:1130. doi: 10.3389/fphar.2020.01130. eCollection 
      2020.